Develops gene therapies for sickle cell disease and genetic disorders.
Jun 2026Revenue $156M/yrExpenses $534M/yr
No trendCash runway ≈ 3.1 years from Jun 2026
Figures by year
When will Beam Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $156M and expenses $534M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $140M | $523M | −$384M |
| Dec 2024 | $63.5M | $479M | −$416M |
| Dec 2023 | $378M | $554M | −$176M |
| Dec 2022 | $60.9M | $399M | −$338M |
| Dec 2021 | $51.8M | $444M | −$392M |
| Dec 2020 | $24.0K | $133M | −$133M |
| Dec 2019 | $18.0K | $75.2M | −$75.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.